Screener
Enliven Therapeutics ELVN Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other expense | — | (47) |
| Total other income (expense), net | 4,196 | 3,149 |
| Net loss | (23,627) | (28,544) |
| Other comprehensive income (loss): | ||
| Net unrealized losses on marketable securities | (716) | (71) |
| Comprehensive loss | $(24,343) | $(28,615) |
| Net loss per share, basic and diluted | $(0.38) | $(0.57) |
| Weighted-average shares outstanding, basic and diluted | 62,799,326 | 50,051,283 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Enliven Therapeutics (ELVN) reported comprehensive income (loss), net of tax, attributable to parent of -$24.34M in Q1 2026.
- How has Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 14.9% year-over-year, from -$28.62M to -$24.34M.
- What is the long-term trend for Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 19.1% compound annual growth rate (CAGR), from -$51.4M to -$103.42M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a comprehensive view of the company's total financial performance and changes in net worth during a reporting period. This figure is essential for assessing the full impact of market and economic factors on the company's capital base.
Ask your AI about Enliven Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude